Printer Friendly

NEORX AND BOEHRINGER INGELHEIM COMPLETE STRATEGIC ALLIANCE

 NEORX AND BOEHRINGER INGELHEIM COMPLETE STRATEGIC ALLIANCE
 SEATTLE, Sept. 29 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) today announced completion of a strategic alliance with Boehringer Ingelheim International GmbH (BI).
 Under the terms of the agreement, NeoRx received $8 million for BI's purchase of two million shares of NeoRx common stock, the issuance to BI of a common stock purchase warrant for an additional 2.5 million shares and the grant of product licenses to BI. NeoRx will receive an additional $3.6 million for 852,000 shares of NeoRx common stock when the results of a limited trial to qualify BI as the manufacturer of the OncoTrac(R) products are filed with the Food and Drug Administration. Under certain circumstances BI may receive a warrant to purchase up to an additional 500,000 shares.
 Under royalty-bearing license agreements, BI receives worldwide manufacturing rights and marketing rights outside the United States for the OncoTrac products; NeoRx maintains U.S. marketing rights. In addition, BI will have the right to incorporate certain NeoRx technology into its own products.
 "We are pleased to conclude these transactions with Boehringer Ingelheim, and look forward to future collaborations that capitalize on the strategic strengths of each company," said Paul G. Abrams, M.D., J.D., NeoRx's president and CEO.
 In January, NeoRx announced it had received a letter from the FDA regarding its OncoTrac Small Cell Lung Cancer (SCLC) Imaging product. The letter indicated that the FDA had no questions on the clinical utility of the product and NeoRx believes the only outstanding issue regarding the product is to qualify BI as the manufacturer. Personnel of both companies have been working together for many months to expedite production of the OncoTrac product so NeoRx can submit the data necessary to qualify BI as the manufacturer.
 "Our phase III trial showed OncoTrac-SCLC to be the most sensitive test for determining how far the cancer had spread and to be as accurate as the entire battery of standard tests currently used," said Dr. Abrams. "Additionally, the cost of using OncoTrac-SCLC is expected to be lower than the current battery of standard tests and the results from the use of OncoTrac-SCLC will be available sooner than the results from the standard battery."
 Boehringer Ingelheim is an international research-oriented pharmaceutical company with headquarters in Ingelheim on the Rhine, Germany. The range of its pharmaceutical specialties includes cardiovascular and pulmonary diseases, gastrointestinal and central nervous system disorders, inflammatory diseases and viral infections. In addition to the comprehensive basic research in its traditional areas, BI is continuing to widen its research activities in the field of biotechnology. The commitment to OncoTrac reflects BI's intention to step up its growing involvement in the hospital business.
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human illnesses with a primary focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA for two OncoTrac cancer imaging products and has completed a phase III trial for a third. Targeted biopharmaceuticals to treat cancer, restenosis after angioplasty and autoimmune diseases are in pre-clinical testing.
 -0- 9/29/92
 /CONTACT: Robert M. Littauer, vice president, chief financial officer and treasurer of NeoRx, 206-286-2519; or Anthony J. Russo or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX) CO: NeoRx Corporation; Boehringer Ingelheim International GmbH ST: Washington IN: MTC SU:


GK-TS -- NY012 -- 4243 09/29/92 09:16 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 29, 1992
Words:572
Previous Article:FAR WEST INDUSTRIES ANNOUNCES RESULTS
Next Article:AFFINITY BIOTECH APPOINTS TWO BOARD MEMBERS TO NEW SEATS AND APPOINTS NEW DIRECTOR OF ANALYTICAL SCIENCES
Topics:


Related Articles
NEORX REPORTS 1992 FOURTH QUARTER RESULTS
NEORX ANNOUNCES $9 MILLION FINANCING
NEORX COMPLETES $9 MILLION FINANCING
NEORX COMPLETES $9 MILLION FINANCING
NEORX REPORTS THIRD QUARTER 1993 RESULTS
NEORX'S AVICIDIN ADVANCES IN PHASE I II CANCER THERAPY TRIALS
ANSAN, INC. ANNOUNCES ACQUISITION OF RIGHTS TO DRUG FOR PANCREATITIS FROM BOEHRINGER INGELHEIM
Ethical Holdings Plc Announces Major Agreement With Boehringer Ingelheim For Morphine Once-Daily Tablet
Synapse Publishing, Inc. Announces Sponsorship Agreement with Boehringer Ingelheim for Innovative Stroke Patient Management Tool
Biofocus plc and Boehringer Ingelheim Pharmaceuticals, Inc. Enter Lead Optimisation Agreement.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters